Biomarker & Intervention Discovery

Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

This page lists 10 druggable gene targets, 42 approved or trial-tested drug candidates and 14 recent clinical trials for Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS), with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

NIH funding$22MFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionPartial spontaneous remission in 20-30% at 2 years; complete resolution rare; chronic pain condition with significant…
Best-intervention remissionMultimodal approach (dietary modification + physical therapy + neuromodulation + intravesical therapy): 50-70% overall…
Gap sizeVery large — no FDA-approved treatment; management is symptomatic and highly individualised
Primary barrierbiological + practice
Full remission profile →
Research Tracker Chronic Disease Interventions Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

Remission & chronicity

Spontaneous remission
Partial spontaneous remission in 20-30% at 2 years; complete resolution rare; chronic pain condition with significant disability; no biomarker-defined diagnosis complicates studies
Best-intervention remission
Multimodal approach (dietary modification + physical therapy + neuromodulation + intravesical therapy): 50-70% overall treatment response but rarely complete remission; intravesical heparin + lidocaine + sodium bicarbonate: 70-80% short-term response; sacral neuromodulation: 48-60% significant improvement at 2 years; cyclosporine A (oral): 75% improvement in Hunner lesion IC vs 19% placebo
Gap size
Very large — no FDA-approved treatment; management is symptomatic and highly individualised
Primary barrier
biological + practice
Only pentosan polysulfate sodium (Elmiron, FDA approved 1996) has FDA approval for IC/BPS, and this is now associated with maculopathy (pigmentary maculopathy) with long-term use; Hunner lesion IC (25% of cases) is a distinct pathological entity with different treatment response than non-Hunner IC; diagnostic heterogeneity makes clinical trials extremely difficult

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

HRH1 374HRH2 231IL6 181NGF 9P2RX3 202PTGS2 309SCN9A 280TNF 287TRPA1 186TRPV1 187

HRH1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
HISTAMINE ↑ activates Mechanistic 13.0 nM (EC50) DGIdb
RISPERIDONE ↓ inhibits Mechanistic 2.6 nM (Ki) DGIdb
EPINASTINE ↓ inhibits Mechanistic DGIdb
PYRILAMINE ↓ inhibits Mechanistic 12.59 nM (IC50) DGIdb
ORPHENADRINE ? unclear Mechanistic DGIdb
MIZOLASTINE ↓ inhibits Mechanistic DGIdb
BETAHISTINE ↑ activates Mechanistic DGIdb
METHAPYRILENE FUMARATE ↓ inhibits Mechanistic DGIdb
MIANSERIN ? unclear Mechanistic 3.388 nM (IC50) DGIdb
MEQUITAZINE ↓ inhibits Mechanistic DGIdb
SERTINDOLE ↓ inhibits Mechanistic 570.0 nM (Ki) DGIdb
BROMPHENIRAMINE ? unclear Mechanistic DGIdb
LORATADINE ↓ inhibits Mechanistic DGIdb
TRIMEPRAZINE ? unclear Mechanistic DGIdb
BU-E 47 ↓ inhibits Mechanistic DGIdb
DEXCHLORPHENIRAMINE MALEATE ? unclear Mechanistic DGIdb
AZELASTINE ↓ inhibits Mechanistic DGIdb
ASENAPINE ↓ inhibits Mechanistic DGIdb
BROMODIPHENHYDRAMINE ? unclear Mechanistic DGIdb
OLOPATADINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
BEPOTASTINE BESILATE ? unclear Mechanistic DGIdb
FEXOFENADINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
PROPIOMAZINE ? unclear Mechanistic DGIdb
CETIRIZINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
DIPHENHYDRAMINE ↓ inhibits Mechanistic DGIdb
ARPROMIDINE ↓ inhibits Mechanistic DGIdb
PHENIRAMINE ? unclear Mechanistic DGIdb
QUETIAPINE FUMARATE ↓ inhibits Mechanistic DGIdb
AZATADINE ? unclear Mechanistic DGIdb
DOXEPIN HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
TRIPROLIDINE ↓ inhibits Mechanistic DGIdb
PROMETHAZINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
HYDROXYZINE ↓ inhibits Mechanistic DGIdb
ILOPERIDONE ? unclear Mechanistic DGIdb
PEMIROLAST ? unclear Mechanistic DGIdb
CHLORPHENIRAMINE POLISTIREX ↓ inhibits Mechanistic DGIdb
DIMETHINDENE ↓ inhibits Mechanistic 0.6918 nM (Ki) DGIdb
VAPITADINE ? unclear Mechanistic DGIdb
ARIPIPRAZOLE LAUROXIL ↓ inhibits Mechanistic DGIdb
BRILAROXAZINE ? unclear Mechanistic DGIdb

Showing top 40 of 374 agents ranked by evidence tier.

HRH2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NIZATIDINE ? unclear Mechanistic DGIdb
FAMOTIDINE ↓ inhibits Mechanistic DGIdb
TIOTIDINE ↓ inhibits Mechanistic DGIdb
BETAZOLE ? unclear Mechanistic DGIdb
EPINASTINE ? unclear Mechanistic DGIdb
RANITIDINE BISMUTH CITRATE ↓ inhibits Mechanistic DGIdb
HISTAMINE ? unclear Mechanistic 463.0 nM (EC50) DGIdb
ST-1006 ↑ activates Mechanistic DGIdb
INCB-38579 ↓ inhibits Mechanistic DGIdb
CIMETIDINE ↓ inhibits Mechanistic DGIdb
CIPROXIFAN ↓ inhibits Mechanistic DGIdb
ABT-239 ↓ inhibits Mechanistic DGIdb
CIMETIDINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
AMTHAMINE ↑ activates Mechanistic DGIdb
EBROTIDINE ↓ inhibits Mechanistic DGIdb
METHANTHELINE BROMIDE ↓ inhibits Mechanistic DGIdb
UR-PG146 ↑ activates Mechanistic DGIdb
ASENAPINE ? unclear Mechanistic DGIdb
DOXEPIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
PITOLISANT ↓ inhibits Mechanistic DGIdb
BETAZOLE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
MK-0249 ↓ inhibits Mechanistic DGIdb
OXO-ARPROMIDINE ↑ activates Mechanistic DGIdb
RANITIDINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
LAFUTIDINE ↓ inhibits Mechanistic DGIdb
TOLAZOLINE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
JNJ-39758979 ↓ inhibits Mechanistic DGIdb
BURIMAMIDE ↑ activates Mechanistic 3981.07 nM (Ki) DGIdb
IMPROMIDINE ↑ activates Mechanistic DGIdb
CONESSINE ↓ inhibits Mechanistic DGIdb
CLOBENPROPIT ↓ inhibits Mechanistic DGIdb
ARPROMIDINE ↑ activates Mechanistic DGIdb
TOLAZOLINE ? unclear Mechanistic Open Targets
METHANTHELINE ? unclear Mechanistic Open Targets
VUF-5297 ↑ activates Mechanistic 696.0 nM (EC50) ChEMBL
CHEMBL72424 ↓ inhibits Mechanistic 10000.0 nM (Ki) ChEMBL
CHEMBL70603 ↓ inhibits Mechanistic 10000.0 nM (Ki) ChEMBL
CHEMBL44220 ↓ inhibits Mechanistic 19952.62 nM (Ki) ChEMBL
CHEMBL72571 ↓ inhibits Mechanistic 3981.07 nM (Ki) ChEMBL
CHEMBL310087 ↓ inhibits Mechanistic 12589.25 nM (Ki) ChEMBL

Showing top 40 of 231 agents ranked by evidence tier.

IL6

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CLAZAKIZUMAB ↓ inhibits Mechanistic DGIdb
MIDOSTAURIN ? unclear Mechanistic DGIdb
ECHINACEA EXTRACT ? unclear Mechanistic DGIdb
NELFINAVIR ? unclear Mechanistic DGIdb
SELECTIVE ESTROGEN RECEPTOR MODULATOR ? unclear Mechanistic DGIdb
SIGNAL TRANSDUCTION INHIBITOR ? unclear Mechanistic DGIdb
OLOKIZUMAB ? unclear Mechanistic DGIdb
IBUDILAST ? unclear Mechanistic DGIdb
VITAMIN A PALMITATE ? unclear Mechanistic DGIdb
IFOSFAMIDE ? unclear Mechanistic DGIdb
SITAGLIPTIN ? unclear Mechanistic DGIdb
METRONIDAZOLE ? unclear Mechanistic DGIdb
PEGINTERFERON ALFA-2A ? unclear Mechanistic DGIdb
PACIBEKITUG ↓ inhibits Mechanistic DGIdb
PEGINTERFERON ALFA-2B ? unclear Mechanistic DGIdb
SIRUKUMAB ↓ inhibits Mechanistic DGIdb
HMG-COA REDUCTASE INHIBITOR ? unclear Mechanistic DGIdb
SAFINGOL ? unclear Mechanistic DGIdb
ENZYME INHIBITOR ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
GALLIUM NITRATE ? unclear Mechanistic DGIdb
RITUXIMAB ? unclear Mechanistic DGIdb
INFLIXIMAB ? unclear Mechanistic DGIdb
C326 ? unclear Mechanistic DGIdb
GEMFIBROZIL ? unclear Mechanistic DGIdb
ZILTIVEKIMAB ? unclear Mechanistic DGIdb
INSULIN, REGULAR, HUMAN ? unclear Mechanistic DGIdb
OSIMERTINIB ? unclear Mechanistic DGIdb
BINETRAKIN ? unclear Mechanistic DGIdb
ALOGLIPTIN ? unclear Mechanistic DGIdb
TENELIGLIPTIN ? unclear Mechanistic DGIdb
CHINESE HERBS ? unclear Mechanistic DGIdb
TOCILIZUMAB ? unclear Mechanistic DGIdb
LINAGLIPTIN ? unclear Mechanistic DGIdb
DOCETAXEL ANHYDROUS ? unclear Mechanistic DGIdb
VILDAGLIPTIN ? unclear Mechanistic DGIdb
LINEZOLID ? unclear Mechanistic DGIdb
SELENIUM ? unclear Mechanistic DGIdb
SAQUINAVIR ? unclear Mechanistic DGIdb
PAREGORIC ? unclear Mechanistic DGIdb

Showing top 40 of 181 agents ranked by evidence tier.

NGF

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
FASINUMAB ? unclear Mechanistic DGIdb
CERE-110 ? unclear Mechanistic DGIdb
TANEZUMAB ? unclear Mechanistic DGIdb
FRUNEVETMAB ~ modulates Mechanistic DGIdb
FULRANUMAB ↓ inhibits Mechanistic DGIdb
PG-110 ↓ inhibits Mechanistic DGIdb
BEDINVETMAB ~ modulates Mechanistic DGIdb
MEDI-578 ↓ inhibits Mechanistic DGIdb
CHEMBL1397270 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL

P2RX3

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
FILAPIXANT ↓ inhibits Mechanistic DGIdb
GEFAPIXANT ↓ inhibits Mechanistic DGIdb
SURAMIN ↓ inhibits Mechanistic 3000.0 nM (EC50) DGIdb
CAMLIPIXANT ↓ inhibits Mechanistic DGIdb
RO3 ↓ inhibits Mechanistic DGIdb
BZATP ↑ activates Mechanistic DGIdb
ΑΒ-MEATP ↑ activates Mechanistic DGIdb
AF353 ↓ inhibits Mechanistic DGIdb
ELIAPIXANT ↓ inhibits Mechanistic DGIdb
ADENOSINE TRIPHOSPHATE ↑ activates Mechanistic 340.0 nM (EC50) DGIdb
A317491 ↓ inhibits Mechanistic DGIdb
AF-906 ↓ inhibits Mechanistic DGIdb
TNP-ATP ↓ inhibits Mechanistic 0.9 nM (EC50) DGIdb
SIVOPIXANT ↓ inhibits Mechanistic DGIdb
SPINORPHIN ~ modulates Mechanistic 0.0481 nM (IC50) DGIdb
GEFAPIXANT CITRATE ↓ inhibits Mechanistic DGIdb
CHEMBL335206 ↑ activates Mechanistic 8800.0 nM (EC50) ChEMBL
CHEMBL1628528 ↓ inhibits Mechanistic 2800.0 nM (IC50) ChEMBL
CHEMBL339386 ↑ activates Mechanistic 80.0 nM (EC50) ChEMBL
PHOSPHOMETHYLPHOSPHONIC ACID ADENYLATE ESTER ↑ activates Mechanistic 9200.0 nM (EC50) ChEMBL
CHEMBL216504 ↓ inhibits Mechanistic 28500.0 nM (IC50) ChEMBL
DIPHOSPHOMETHYLPHOSPHONIC ACID ADENOSYL ESTER ↑ activates Mechanistic 740.0 nM (EC50) ChEMBL
ATPGAMMAS ↑ activates Mechanistic 690.0 nM (EC50) ChEMBL
CHEMBL129841 ↑ activates Mechanistic 13000.0 nM (EC50) ChEMBL
ISOPPADS ↓ inhibits Mechanistic 84.0 nM (IC50) ChEMBL
CHEMBL74121 ↓ inhibits Mechanistic 58300.0 nM (IC50) ChEMBL
CHEMBL133930 ↓ inhibits Mechanistic 1000.0 nM (IC50) ChEMBL
CHEMBL130094 ↑ activates Mechanistic 350.0 nM (EC50) ChEMBL
CHEMBL337062 ↑ activates Mechanistic 17.0 nM (EC50) ChEMBL
CHEMBL336208 ↑ activates Mechanistic 350.0 nM (EC50) ChEMBL
CHEMBL69234 ↑ activates Mechanistic 240.0 nM (EC50) ChEMBL
DIADENOSINE TETRAPHOSPHATE ↑ activates Mechanistic 500.0 nM (EC50) ChEMBL
CHEMBL413145 ↓ inhibits Mechanistic 354.81 nM (IC50) ChEMBL
CHEMBL397926 ↓ inhibits Mechanistic 82.4 nM (IC50) ChEMBL
CHEMBL395723 ↓ inhibits Mechanistic 32.4 nM (IC50) ChEMBL
CHEMBL238310 ↓ inhibits Mechanistic 14.3 nM (IC50) ChEMBL
CHEMBL599760 ↓ inhibits Mechanistic 398.11 nM (IC50) ChEMBL
CHEMBL2010928 ↓ inhibits Mechanistic 1360.0 nM (IC50) ChEMBL
CHEMBL2010929 ↓ inhibits Mechanistic 618.0 nM (IC50) ChEMBL
CHEMBL2010930 ↓ inhibits Mechanistic 327.0 nM (IC50) ChEMBL

Showing top 40 of 202 agents ranked by evidence tier.

PTGS2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CURCUMIN PYRAZOLE ? unclear Mechanistic DGIdb
CAPECITABINE ? unclear Mechanistic DGIdb
DIFLUNISAL ↓ inhibits Mechanistic DGIdb
ROFECOXIB ↓ inhibits Mechanistic 530.0 nM (IC50) DGIdb
KETOROLAC TROMETHAMINE ↓ inhibits Mechanistic DGIdb
DEXIBUPROFEN ↓ inhibits Mechanistic DGIdb
BALSALAZIDE ? unclear Mechanistic DGIdb
ESFLURBIPROFEN ↓ inhibits Mechanistic DGIdb
NAPROXEN ETEMESIL ? unclear Mechanistic DGIdb
SUPROFEN ↓ inhibits Mechanistic DGIdb
PEPTIDE 30 [PMID: 27019010] ↓ inhibits Mechanistic DGIdb
NEPAFENAC ↓ inhibits Mechanistic DGIdb
APRICOXIB ↓ inhibits Mechanistic DGIdb
APAZONE ↓ inhibits Mechanistic DGIdb
SALICYLIC ACID ? unclear Mechanistic DGIdb
TIAPROFENIC ACID ? unclear Mechanistic DGIdb
KETOPROFEN ↓ inhibits Mechanistic DGIdb
RESERPINE ? unclear Mechanistic DGIdb
NS-398 ↓ inhibits Mechanistic DGIdb
NABUMETONE ↓ inhibits Mechanistic DGIdb
SULINDAC ↓ inhibits Mechanistic DGIdb
ETODOLAC ↓ inhibits Mechanistic DGIdb
MEFENAMIC ACID ↓ inhibits Mechanistic DGIdb
DICLOFENAC SODIUM ↓ inhibits Mechanistic DGIdb
ETORICOXIB ↓ inhibits Mechanistic DGIdb
VALDECOXIB ↓ inhibits Mechanistic DGIdb
IBUFENAC ↓ inhibits Mechanistic DGIdb
DEXKETOPROFEN ↓ inhibits Mechanistic DGIdb
GLAFENINE ↓ inhibits Mechanistic DGIdb
COMPOUND 9 [KUMAR ET AL., 2019] ↓ inhibits Mechanistic DGIdb
RESVERATROL ↓ inhibits Mechanistic DGIdb
SWE101 ↓ inhibits Mechanistic DGIdb
INDOMETHACIN ↓ inhibits Mechanistic 5.9 nM (IC50) DGIdb
NAPROXCINOD ↓ inhibits Mechanistic DGIdb
HR1405-01 ↓ inhibits Mechanistic DGIdb
DICLOFENAC ETALHYALURONATE SODIUM ↓ inhibits Mechanistic DGIdb
COMPOUND 12A [PMID: 29031075] ↓ inhibits Mechanistic DGIdb
TOLMETIN SODIUM ↓ inhibits Mechanistic DGIdb
OXYPHENBUTAZONE ↓ inhibits Mechanistic DGIdb
DICLOFENAC POTASSIUM ↓ inhibits Mechanistic DGIdb

Showing top 40 of 309 agents ranked by evidence tier.

SCN9A

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TETRODOTOXIN ↓ inhibits Mechanistic DGIdb
XEN403 ↓ inhibits Mechanistic DGIdb
IRAMPANEL ↓ inhibits Mechanistic DGIdb
XEN907 ↓ inhibits Mechanistic DGIdb
N-ME-AMINOPYRIMIDINONE 9 ↓ inhibits Mechanistic DGIdb
PF‐06526290 ↓ inhibits Mechanistic DGIdb
QUINIDINE POLYGALACTURONATE ↓ inhibits Mechanistic DGIdb
VIXOTRIGINE ↓ inhibits Mechanistic DGIdb
LIDOCAINE ↓ inhibits Mechanistic DGIdb
FUNAPIDE ↓ inhibits Mechanistic DGIdb
CD2+ ↓ inhibits Mechanistic DGIdb
PHENYTOIN SODIUM ↓ inhibits Mechanistic DGIdb
HEXYLCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ESLICARBAZEPINE ACETATE ↓ inhibits Mechanistic DGIdb
DICHLOROBENZYL ALCOHOL ↓ inhibits Mechanistic DGIdb
PROPOFOL ? unclear Mechanistic DGIdb
OXCARBAZEPINE ↓ inhibits Mechanistic DGIdb
ORPHENADRINE CITRATE ↓ inhibits Mechanistic DGIdb
NERISPIRDINE ↓ inhibits Mechanistic DGIdb
CHLOROPROCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
MEPHENYTOIN ↓ inhibits Mechanistic DGIdb
ANP-230 ↓ inhibits Mechanistic DGIdb
ABBV-318 ↓ inhibits Mechanistic DGIdb
MEPIVACAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
AMOROLFINE ↓ inhibits Mechanistic DGIdb
RUFINAMIDE ↓ inhibits Mechanistic DGIdb
EVENAMIDE ↓ inhibits Mechanistic DGIdb
SAFINAMIDE ? unclear Mechanistic DGIdb
NKTR-171 ↓ inhibits Mechanistic DGIdb
RG6029 ↓ inhibits Mechanistic DGIdb
RALFINAMIDE ↓ inhibits Mechanistic DGIdb
ZONISAMIDE ↓ inhibits Mechanistic DGIdb
BIIB-095 ? unclear Mechanistic DGIdb
RG7893 ↓ inhibits Mechanistic DGIdb
ARTICAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
DISOPYRAMIDE PHOSPHATE ↓ inhibits Mechanistic DGIdb
PROPOXYCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
TOCAINIDE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
TETRACAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
MERETHOXYLLINE PROCAINE ↓ inhibits Mechanistic DGIdb

Showing top 40 of 280 agents ranked by evidence tier.

TNF

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
DICLOFENAC SODIUM ? unclear Mechanistic DGIdb
RDP58 ? unclear Mechanistic DGIdb
METHYLENE BLUE ? unclear Mechanistic DGIdb
ORTATAXEL ? unclear Mechanistic DGIdb
CERTOLIZUMAB PEGOL ↓ inhibits Mechanistic DGIdb
OZORALIZUMAB ↓ inhibits Mechanistic DGIdb
THALIDOMIDE ? unclear Mechanistic DGIdb
HUANG LIAN ? unclear Mechanistic DGIdb
GOLIMUMAB ↓ inhibits Mechanistic DGIdb
CYCLOSPORINE ? unclear Mechanistic DGIdb
DOCETAXEL ANHYDROUS ? unclear Mechanistic DGIdb
HALOFUGINONE ? unclear Mechanistic DGIdb
ETANERCEPT ↓ inhibits Mechanistic DGIdb
ISIS 104838 ? unclear Mechanistic DGIdb
GEMCITABINE ? unclear Mechanistic DGIdb
INDOMETHACIN ? unclear Mechanistic DGIdb
INSULIN, REGULAR, HUMAN ? unclear Mechanistic DGIdb
DIDANOSINE ? unclear Mechanistic DGIdb
5,7-DIHYDROXY-4-METHYLCOUMARIN ? unclear Mechanistic DGIdb
SOBLIDOTIN ? unclear Mechanistic DGIdb
STAVUDINE ? unclear Mechanistic DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
MEROPENEM ANHYDROUS ? unclear Mechanistic DGIdb
AMPHOTERICIN B LIPOSOMAL ? unclear Mechanistic DGIdb
MIDAZOLAM HYDROCHLORIDE ? unclear Mechanistic DGIdb
RIFAMPIN ? unclear Mechanistic DGIdb
AVX-470 ? unclear Mechanistic DGIdb
KETOROLAC TROMETHAMINE ? unclear Mechanistic DGIdb
PRAZOSIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
RISPERIDONE ? unclear Mechanistic DGIdb
BENZO[E]PYRENE ? unclear Mechanistic DGIdb
ETHAMBUTOL HYDROCHLORIDE ? unclear Mechanistic DGIdb
REMTOLUMAB ↓ inhibits Mechanistic DGIdb
SPIRONOLACTONE ? unclear Mechanistic DGIdb
OMEPRAZOLE ? unclear Mechanistic DGIdb
CARBOPLATIN ? unclear Mechanistic DGIdb
MITOMYCIN C ANALOG KW-2149 ? unclear Mechanistic DGIdb
NAFAMOSTAT ? unclear Mechanistic DGIdb
ABBV-3373 ~ modulates Mechanistic DGIdb
BACILLUS CALMETTE-GUERIN ANTIGEN ? unclear Mechanistic DGIdb

Showing top 40 of 287 agents ranked by evidence tier.

TRPA1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
ASP7663 ↑ activates Mechanistic DGIdb
NPPB ↑ activates Mechanistic DGIdb
VOACANGINE ? unclear Mechanistic DGIdb
METHYLGLYOXAL ↑ activates Mechanistic DGIdb
ALLYL ISOTHIOCYANATE ↑ activates Mechanistic 33500.0 nM (EC50) DGIdb
BENZYL BROMIDE ↑ activates Mechanistic 12000.0 nM (EC50) DGIdb
1,6-HEXAMETHYLENE DIISOCYANATE ↑ activates Mechanistic DGIdb
BROMOACETONE ↑ activates Mechanistic DGIdb
ACETALDEHYDE ↑ activates Mechanistic DGIdb
ISOVELLERAL ↑ activates Mechanistic 590.0 nM (EC50) DGIdb
POLYGODIAL ↑ activates Mechanistic 59.0 nM (EC50) DGIdb
CISPLATIN ? unclear Mechanistic DGIdb
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
A-967079 ↓ inhibits Mechanistic DGIdb
NITROOLEIC ACID ↑ activates Mechanistic DGIdb
PHENETHYLISOTHIOCYANATE ? unclear Mechanistic 10000.0 nM (EC50) DGIdb
PF-4840154 ↑ activates Mechanistic DGIdb
4-HYDROXYNONENAL ? unclear Mechanistic DGIdb
AM-0902 ↓ inhibits Mechanistic DGIdb
ACROLEIN ↑ activates Mechanistic 5000.0 nM (EC50) DGIdb
1'-ACETOXYCHAVICOL ACETATE ↑ activates Mechanistic DGIdb
GDC-0334 ↓ inhibits Mechanistic DGIdb
METHYL ISOCYANATE ↑ activates Mechanistic DGIdb
BUTAMBEN ↓ inhibits Mechanistic DGIdb
ERUCIN ? unclear Mechanistic DGIdb
CHLOROPICRIN ↑ activates Mechanistic DGIdb
SALIRASIB ↑ activates Mechanistic 5000.0 nM (EC50) DGIdb
BUTAMBEN PICRATE ↓ inhibits Mechanistic DGIdb
MENTHOL ↑ activates Mechanistic 28400.0 nM (EC50) DGIdb
CHLOROBENZYLIDENE MALONONITRILE ↑ activates Mechanistic DGIdb
HC030031 ↓ inhibits Mechanistic DGIdb
URB597 ↑ activates Mechanistic DGIdb
JT010 ↑ activates Mechanistic DGIdb
DIBUTYLPHTHALATE ↑ activates Mechanistic DGIdb
AP18 ↓ inhibits Mechanistic DGIdb
TCS 5861528 ↓ inhibits Mechanistic DGIdb
APOMORPHINE ↑ activates Mechanistic DGIdb
CB-189625 ↓ inhibits Mechanistic DGIdb
BENZOQUINONE ↑ activates Mechanistic DGIdb
GRC-17536 ↓ inhibits Mechanistic DGIdb

Showing top 40 of 186 agents ranked by evidence tier.

TRPV1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
RHTX ↑ activates Mechanistic DGIdb
ABT-102 ↓ inhibits Mechanistic DGIdb
ASIVATREP ↓ inhibits Mechanistic DGIdb
BCTC ↓ inhibits Mechanistic DGIdb
MAVATREP ↓ inhibits Mechanistic DGIdb
POLYGODIAL ? unclear Mechanistic DGIdb
ALLICIN ↓ inhibits Mechanistic DGIdb
JTS-653 ↓ inhibits Mechanistic DGIdb
SB452533 ↓ inhibits Mechanistic DGIdb
MR-1817 ↓ inhibits Mechanistic DGIdb
GRC-6211 ↓ inhibits Mechanistic DGIdb
ACETAMINOPHEN ↑ activates Mechanistic DGIdb
DWP05195 ↓ inhibits Mechanistic DGIdb
STREPTOZOCIN ? unclear Mechanistic DGIdb
CAPSAICIN ↑ activates Mechanistic 19.95 nM (EC50) DGIdb
AMG517 ↓ inhibits Mechanistic DGIdb
5S-HETE ↑ activates Mechanistic DGIdb
BENZYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
MASOPROCOL ? unclear Mechanistic DGIdb
[3H]RESINIFERATOXIN ↑ activates Mechanistic DGIdb
[3H]A778317 ↓ inhibits Mechanistic DGIdb
CAPSAZEPINE ↓ inhibits Mechanistic 120.0 nM (Ki) DGIdb
NABIXIMOLS ? unclear Mechanistic DGIdb
H+ ↑ activates Mechanistic DGIdb
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic DGIdb
NADA ↓ inhibits Mechanistic DGIdb
ZUCAPSAICIN ↑ activates Mechanistic DGIdb
SB366791 ↓ inhibits Mechanistic DGIdb
GRC-15300 ? unclear Mechanistic DGIdb
MRS-1477 ~ modulates Mechanistic DGIdb
ANANDAMIDE ↑ activates Mechanistic DGIdb
JNJ17203212 ↓ inhibits Mechanistic DGIdb
LEVODOPA ? unclear Mechanistic DGIdb
INDOMETHACIN ? unclear Mechanistic DGIdb
AZD1386 ↓ inhibits Mechanistic DGIdb
CAMPHOR OIL ↑ activates Mechanistic DGIdb
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
VOACANGINE ? unclear Mechanistic DGIdb
FERRUGINENE B ? unclear Mechanistic DGIdb
PHENYLACETYLRINVANIL ↑ activates Mechanistic DGIdb

Showing top 40 of 187 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS): recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS Recruiting
NCT05737121 Phase: 2 Started: 2023-05-22

This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and its individual components (heparin sodium and lidocaine hydrochloride (HC...

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) Recruiting
NCT06394830 Phase: 2 Started: 2024-12-13

This is an open-label study that will enroll participants with Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). The study will assess PRN (as needed) dosing of up to 6 intravesical (via catheter) doses of VNX001 (study drug) to treat acute instances of moderate to severe bladder pain over a 1...

Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) Completed
NCT05141006 Phase: 2 Started: 2022-03-29

Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic and debilitating urological complex of disorders characterized by symptoms of bladder pain or discomfort, mostly upon bladder filling, and often accompanied by lower urinary tract symptoms (LUTS). This study will assess how safe and e...

PK and Safety of SI-722 in IC/BPS Completed
NCT04208087 Phase: 1/2 Started: 2020-03-30

This study is designed randomized, double-blind, placebo-controlled trial in Interstitial Cystitis/Bladder Pain Syndrome patients.

Clinical Trial Comparing Two Bladder Instillations for IC/BPS Completed
NCT03463915 Phase: 3 Started: 2019-01-25

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a condition that results in long-term bladder and pelvic pain. IC/BPS affects women more often than men. How the disorder develops is not completely known. Bladder instillation is a commonly used treatment in which a mixture of different ingred...

Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome Recruiting
NCT06096597 Phase: 2/3 Started: 2024-07-24

Interstitial cystitis/painful bladder syndrome (IC/PBS) is a clinical syndrome in which patients report symptoms of bladder and/or pelvic pain with pressure and/ or discomfort associated with urinary frequency and urgency. The primary objective of this study is to determine the efficacy of amniotic ...

Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis Recruiting
NCT04734106 Phase: Early 1 Started: 2025-02-18

The purpose of this study is to assess the safety and efficacy of super-concentrated, freeze-dried aloe vera capsules for treatment of interstitial cystitis.

Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome Completed
NCT06285214 Phase: 1 Started: 2022-05-26

The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.

EA for BPS: An RCT and Study for Central Mechanism Recruiting
NCT05279963 Phase: N/A Started: 2022-03-16

This is a randomized controlled and assessor-blinded design trial to evaluate the efficacy and safety of acupuncture for bladder pain syndrome(BPS). All eligible participants will be randomly assigned to the medication group(n=21), EA group(n=42) and SA group(n=21) in a 1:2:1 allocation ratio. Parti...

A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis Completed
NCT03282318 Phase: 2 Started: 2017-09-28

The purpose of this study is to investigate efficacy, safety and tolerability of ASP6294 in female participants with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC). This study will also investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of ASP6294 in female participants with BPS/I...

Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome Completed
NCT04401176 Phase: 2 Started: 2020-09-15

Recognition of interstitial cystitis (IC)/bladder pain syndrome (BPS) is increasing. There is a dire need to develop effective treatment options for these patients as it manifests as more than a physical disease, affecting general and psychological health as well. Existing trials comparing varying b...

The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients Completed
NCT03463499 Phase: N/A Started: 2017-09-22

The efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate after transurethral resection of Hunner lesion in interstitial cystitis/bladder pain syndrome patients. To analyze the number and timing of recurrence based on a long-term follow-up.

Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome Recruiting
NCT04845217 Phase: 1/2 Started: 2021-09-15

The purpose of this study is to assess the use of peppermint oil as a treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).

Intravesical Injection of Dextrose to Improve Lower Urinary Tract Symptoms Caused by Chronic Cystitis Completed
NCT04821882 Phase: N/A Started: 2019-05-01

The pathogenesis of bladder pain syndrome/interstitial cystitis (BPS/IC) is currently unclear. Scholars have put forward different hypotheses, including the function of the extracellular matrix surface of the glycosaminoglycan (GAG) layer, downregulation of tight junction protein, increased urotheli...

Agents Found By Disease-Level Search

Searched directly from “Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

42 agents shown (approved or with trial evidence) — 41 not found by the gene-target search above.

BOTOXNOT in gene-target list

· 3 trials · source: ClinicalTrials.gov
NCT05141006 NCT03103594 NCT00194610

Psychosocial TreatmentNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT06299683 NCT04275297

Onabotulinum Toxin ANOT in gene-target list

Phase 2 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT04401176 NCT02297100

VNX001NOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT06394830 NCT05737121

Neovasculgen®NOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT07391306 NCT07459790

superior hypogastric plexus pulsed radiofrequencyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06256679

ASP3652NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01613586

Hyaluronic Acid and Chondroitin Sulfate (Blad-Care™)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07495072

LiRIS low dose and LiRIS high doseNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01150565

Pulsed Electromagnetic Field (PEMF) TherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04540887

rosiptor (AQX-1125)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01882543

DMSONOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03103594

Heparin & Alkalinized Lidocaine Bladder InstillationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04401176

Bladder instillation WITH triamcinolone acetonideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03463915

Bladder instillation WITHOUT triamcinolone acetonideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03463915

IaluadapterNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06540248

Botulinum toxin ANOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01969773

Cipro (Ciprofloxacin, BAYQ3939)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02555059

LP-08 80mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01393223

LP-08 20mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01393223

TC-3 Gel mixed with Botox (BTX)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01997983

interferential currentNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03844581

Propiverine HydrochlorideNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03844581

UracystNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00150488

2% sodium chondroitin sulfateNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00919113

levofloxacinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00210886

ONO-1110NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06752603

bupivacaine, triamcinolone, and heparin (BTH)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05223244

dimethyl sulfoxide (DMSO)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05223244

Certolizumab pegol

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02497976

Intravesical injection of Platlet Rich Plasma (PRP)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06209008

Clarix FloNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06096597

5% lidocaine/5 mg/ml 0.02% estradiol compound creamNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03844412

NortriptylineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03844412

H&P; ECG; Blood tests; voiding diary; CystoscopyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00056251

omalizumabNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01294878

injections upper aspect of trigone of urinary bladderNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02297100

injections on posterior bladder wall excluding the trigoneNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02297100

AmitriptylineNOT in gene-target list

Phase 3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT05279963

PF-04383119NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00601484

Nitrofurantoin 100 MGNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06387329

Desert Harvest Aloe Vera CapsulesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04734106

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.